Robatumumab Explained

Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.[1]

Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.[2] Merck has since discontinued development.[3]

Notes and References

  1. "robatumumab", p. 337 in: Proposed International Nonproprietary Names: List 100 . 311–67 . WHO Drug Information . 22 . 4 . 2008 . Quality Assurance and Safety of Medicines . Encrenaz C .
  2. Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D . 6 . A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma . Pediatric Blood & Cancer . 63 . 10 . 1761–70 . October 2016 . 27362300 . 5129487 . 10.1002/pbc.26087 .
  3. Web site: Robatumumab . Adis Insight . Springer Nature Switzerland AG .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Robatumumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.